Medical treatment of gastroesophageal reflux disease in the managed care environment

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The goals of management of any disease process tie, to relieve symptoms, heal the process, and prevent complications while minimizing the use of health care resources), including gastroesophageal reflux disease (GERD), are not altered by practicing within a managed care environment. However, short-sightedness sometimes leads one to view outcomes from a narrow focus (costs of treatments, diagnostic tests, etc) instead of evaluating overall cost and outcome. GERD is an example in which short-sighted approaches (using cheaper but less effective pharmaceutical agents) have led to worse outcomes and more costly therapy. A therapy that is less costly but also less effective in preventing symptoms and complications is more expensive than a therapy that costs more but keeps a patient in remission. 'The most expensive therapy is the one that doesn't work.' These simple, underutilized, pharmacoeconomic concepts are the basis for the discussion of GERD and the suggested treatment algorithm that follows.

Original languageEnglish (US)
Pages (from-to)90-99
Number of pages10
JournalSeminars in Gastrointestinal Disease
Volume8
Issue number2
StatePublished - 1997

Fingerprint

Managed Care Programs
Gastroesophageal Reflux
Therapeutics
Costs and Cost Analysis
Pharmaceutical Economics
Health Resources
Disease Management
Routine Diagnostic Tests
Health Care Costs
Delivery of Health Care
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{df151306d6d241e49052a9ab8171ace4,
title = "Medical treatment of gastroesophageal reflux disease in the managed care environment",
abstract = "The goals of management of any disease process tie, to relieve symptoms, heal the process, and prevent complications while minimizing the use of health care resources), including gastroesophageal reflux disease (GERD), are not altered by practicing within a managed care environment. However, short-sightedness sometimes leads one to view outcomes from a narrow focus (costs of treatments, diagnostic tests, etc) instead of evaluating overall cost and outcome. GERD is an example in which short-sighted approaches (using cheaper but less effective pharmaceutical agents) have led to worse outcomes and more costly therapy. A therapy that is less costly but also less effective in preventing symptoms and complications is more expensive than a therapy that costs more but keeps a patient in remission. 'The most expensive therapy is the one that doesn't work.' These simple, underutilized, pharmacoeconomic concepts are the basis for the discussion of GERD and the suggested treatment algorithm that follows.",
author = "Fennerty, {M (Brian)}",
year = "1997",
language = "English (US)",
volume = "8",
pages = "90--99",
journal = "Seminars in Gastrointestinal Disease",
issn = "1049-5118",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Medical treatment of gastroesophageal reflux disease in the managed care environment

AU - Fennerty, M (Brian)

PY - 1997

Y1 - 1997

N2 - The goals of management of any disease process tie, to relieve symptoms, heal the process, and prevent complications while minimizing the use of health care resources), including gastroesophageal reflux disease (GERD), are not altered by practicing within a managed care environment. However, short-sightedness sometimes leads one to view outcomes from a narrow focus (costs of treatments, diagnostic tests, etc) instead of evaluating overall cost and outcome. GERD is an example in which short-sighted approaches (using cheaper but less effective pharmaceutical agents) have led to worse outcomes and more costly therapy. A therapy that is less costly but also less effective in preventing symptoms and complications is more expensive than a therapy that costs more but keeps a patient in remission. 'The most expensive therapy is the one that doesn't work.' These simple, underutilized, pharmacoeconomic concepts are the basis for the discussion of GERD and the suggested treatment algorithm that follows.

AB - The goals of management of any disease process tie, to relieve symptoms, heal the process, and prevent complications while minimizing the use of health care resources), including gastroesophageal reflux disease (GERD), are not altered by practicing within a managed care environment. However, short-sightedness sometimes leads one to view outcomes from a narrow focus (costs of treatments, diagnostic tests, etc) instead of evaluating overall cost and outcome. GERD is an example in which short-sighted approaches (using cheaper but less effective pharmaceutical agents) have led to worse outcomes and more costly therapy. A therapy that is less costly but also less effective in preventing symptoms and complications is more expensive than a therapy that costs more but keeps a patient in remission. 'The most expensive therapy is the one that doesn't work.' These simple, underutilized, pharmacoeconomic concepts are the basis for the discussion of GERD and the suggested treatment algorithm that follows.

UR - http://www.scopus.com/inward/record.url?scp=0030975411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030975411&partnerID=8YFLogxK

M3 - Article

C2 - 9109696

AN - SCOPUS:0030975411

VL - 8

SP - 90

EP - 99

JO - Seminars in Gastrointestinal Disease

JF - Seminars in Gastrointestinal Disease

SN - 1049-5118

IS - 2

ER -